Oppenheimer Remains Bullish on Relypsa (RLYP) Following FDA's Veltassa Approval
Tweet Send to a Friend
Oppenheimer reiterated an Outperform rating and $55.00 price target on Relypsa, Inc. (NASDAQ: RLYP) after the FDA approved Veltassa once-daily ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
